All Systems Go For Novartis 'World-First' Leqvio Pact With England

Some 20 months after unveiling a landmark alliance with NHS England to give at-risk patients speedy access to Leqvio, Novartis AG has now secured reimbursement in the country for the gene silencing cholesterol lower which could be used to treat hundreds of thousands of cardiovascular patients over the next three years.

The wide-ranging "world-first" collaboration, initially trumpeted at the J.P. Morgan Healthcare Conference in January 2020 and almost a year before Leqvio (inclisiran) actually received marketing approval in Europe in December 2020, was heralded as a bid to tackle the healthcare challenge of cardiovascular disease in UK involving quick access, a large-scale trial and manufacturing. Now, the alliance can move into the implementation phase following the positive final recommendation from the National Institute for Health and Care Excellence (NICE)